Published in Clin Vaccine Immunol on January 03, 2007
Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun (1981) 3.16
Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis (2001) 2.41
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun (1993) 2.36
Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis (1997) 2.32
Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol (2002) 2.16
No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine (2004) 2.13
Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun (1997) 2.03
Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology (1998) 1.75
In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol (1996) 1.59
Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol (2000) 1.56
Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J Infect Dis (1999) 1.54
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol (1998) 1.44
Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine (2006) 1.29
Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol (2000) 1.12
The non-specific enhancement of allergy. I. In vivo effects of Bordetella pertussis vaccine on IgE synthesis. Allergy (1983) 1.02
Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection. Proc Natl Acad Sci U S A (2000) 0.98
Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J Infect Dis (2002) 0.96
Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens. J Infect Dis (2000) 0.93
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine (2000) 0.91
Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. Gut (2006) 0.87
Adjuvant activity of various diesel exhaust and ambient particles in two allergic models. J Toxicol Environ Health A (2003) 0.87
Classification of chemical allergens according to cytokine secretion profiles of murine lymph node cells. J Appl Toxicol (1997) 0.87
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand (1997) 0.86
Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr (1999) 0.85
Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Vaccine (1996) 0.84
Increased airway hyperresponsiveness and inflammation in a juvenile mouse model of asthma exposed to air-pollutant aerosol. J Toxicol Environ Health A (1999) 0.83
Pertussis IgE and atopic disease. Allergy (1998) 0.82
Assessment of preferential T-helper 1 or T-helper 2 induction by low molecular weight compounds using the local lymph node assay in conjunction with RT-PCR and ELISA for interferon-gamma and interleukin-4. Toxicol Appl Pharmacol (2000) 0.81
Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model. Clin Diagn Lab Immunol (2005) 0.81
Diphtheria tetanus pertussis poliomyelitis vaccination and reported atopic disorders in 8-12-year-old children. Vaccine (2005) 0.81
Impact of exposure duration by low molecular weight compounds on interferon-gamma and interleukin-4 mRNA expression and production in the draining lymph nodes of mice. Toxicology (2003) 0.79
Lower risk of atopic disorders in whole cell pertussis-vaccinated children. Eur Respir J (2003) 0.78
Cytokine production induced by low-molecular-weight chemicals as a function of the stimulation index in a modified local lymph node assay: an approach to discriminate contact sensitizers from respiratory sensitizers. Toxicol Appl Pharmacol (2002) 0.78
Use of the local lymph node assay in assessment of immune function. Toxicology (2005) 0.77
Effect of acellular pertussis vaccine on the development of allergic sensitization to environmental allergens in adults. J Allergy Clin Immunol (2000) 0.76
Specific immune response in adult medical personnel immunized with acellular pertussis vaccine with special emphasis on T helper cell response. Vaccine (1997) 0.76
Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog (2005) 2.71
Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol (2004) 2.58
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J (2008) 1.69
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One (2010) 1.61
Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (2002) 1.46
Sub-chronic toxicity study in rats orally exposed to nanostructured silica. Part Fibre Toxicol (2014) 1.44
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACS Nano (2012) 1.34
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine (2013) 1.24
Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci (2005) 1.24
Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Res Ther (2012) 1.18
Improving pertussis vaccination. Hum Vaccin (2009) 1.12
Toxicity of coarse and fine particulate matter from sites with contrasting traffic profiles. Inhal Toxicol (2007) 1.12
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03
Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine (2011) 1.03
Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine (2004) 1.02
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol (2008) 0.99
Pertussis: a matter of immune modulation. FEMS Microbiol Rev (2011) 0.99
Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. Int J Food Microbiol (2006) 0.98
An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine (2009) 0.96
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol (2012) 0.92
Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One (2011) 0.91
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun (2004) 0.90
Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology (2012) 0.90
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Inhalation of concentrated particulate matter produces pulmonary inflammation and systemic biological effects in compromised rats. J Toxicol Environ Health A (2005) 0.88
Association of Bordetella pertussis with host immune cells in the mouse lung. Microb Pathog (2003) 0.88
Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine (2009) 0.88
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis (2008) 0.85
Response of spontaneously hypertensive rats to inhalation of fine and ultrafine particles from traffic: experimental controlled study. Part Fibre Toxicol (2006) 0.83
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
Modulation of mammary tumor development in Tg.NK (MMTV/c-neu) mice by dietary fatty acids and life stage-specific exposure to phytoestrogens. Reprod Toxicol (2006) 0.82
Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine (2007) 0.81
Bordetella pertussis isolates, Finland. Emerg Infect Dis (2005) 0.81
Whooping cough in Pakistan: Bordetella pertussis vs Bordetella parapertussis in 2005-2009. Scand J Infect Dis (2011) 0.81
Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. BMC Microbiol (2007) 0.81
The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine (2007) 0.80
Ozone induces clear cellular and molecular responses in the mouse lung independently of the transcription-coupled repair status. J Appl Physiol (1985) (2006) 0.80
Relative sensitivity of developmental and immune parameters in juvenile versus adult male rats after exposure to di(2-ethylhexyl) phthalate. Toxicol Appl Pharmacol (2012) 0.80
Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (Berl) (2015) 0.80
Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine (2013) 0.80
Tissue response in the rat and the mouse to degradable dextran hydrogels. J Biomed Mater Res A (2007) 0.79
Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. Microbes Infect (2007) 0.79
Molecular typing of Bordetella parapertussis isolates circulating in Pakistan. FEMS Immunol Med Microbiol (2011) 0.78
In vitro assessment of sensitizing activity of low molecular weight compounds. Toxicol Appl Pharmacol (2005) 0.78
Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol Med Microbiol (2007) 0.77
Use of the local lymph node assay in assessment of immune function. Toxicology (2005) 0.77
A novel strategy to mimic discontinuous protective epitopes using a synthetic scaffold. Vaccine (2007) 0.76
Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats. Part Fibre Toxicol (2014) 0.76
Statin use and markers of immunity in the Doetinchem cohort study. PLoS One (2013) 0.76
Developmental immunotoxicity in male rats after juvenile exposure to ethanol. Toxicology (2013) 0.76
Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply. Arthritis Res Ther (2013) 0.75
Pertussis in infancy and the association with respiratory and cognitive disorders at toddler age. Vaccine (2011) 0.75
Pertussis toxin relaxes small arteries with no vascular lesions or vascular smooth muscle cell injury. Exp Toxicol Pathol (2004) 0.75
Ultrastructural characterization of effector-target interactions for human neonatal and adult NK cells reveals reduced intercellular surface contacts of neonatal cells. Hum Immunol (2003) 0.75
Induction of skin sensitization is augmented in Nrf2-deficient mice. Arch Toxicol (2012) 0.75
[Pertussis in the Netherlands]. Ned Tijdschr Geneeskd (2010) 0.75